TY - JOUR
T1 - Urinary extracellular vesicles as biomarkers of kidney disease
T2 - From diagnostics to therapeutics
AU - Sun, In O.
AU - Lerman, Lilach O.
N1 - Funding Information:
AbbreviationsConflicts of Interest: Dr. Lerman receives grant funding from Novo Nordisk and is an advisor to Weijian
Funding Information:
Such urinary EVs are appropriate and useful for diagnosis given the ease of collection and Such urinary EVs are appropriate and useful for diagnosis given the ease of collection and ability ability to serve as a “liquid biopsy” to provide information on the pathophysiological state of kidneys. to serve as a “liquid biopsy” to provide information on the pathophysiological state of kidneys. The The availability of a reliable and quick urinary assay of EV biomarkers might support a non-invasive availability of a reliable and quick urinary assay of EV biomarkers might support a non-invasive diagnosis and facilitate adequate individualized management approaches. Additionally, further diagnosis and facilitate adequate individualized management approaches. Additionally, further studies showing the relationship between the number of EVs and renal diseases are needed. The use studies showing the relationship between the number of EVs and renal diseases are needed. The use of EVs as indices of the response to therapy is underutilized and needs further validation. Rigorous of EVs as indices of the response to therapy is underutilized and needs further validation. Rigorous studies to detect and portray EVs will also extend our understanding of their diverse roles in health and studies to detect and portray EVs will also extend our understanding of their diverse roles in health disease, and provide new insight into the origins, diagnosis, and treatment options for renal disease. and disease, and provide new insight into the origins, diagnosis, and treatment options for renal AduitsheoarsCeo. ntributions: I.O.S. performed the initial literature search and wrote the manuscript. L.O.L. supervised, reviewed, obtained funding, corrected the manuscript, and provided final approval of publication for this Author Contributions: I.O.S. performed the initial literature search and wrote the manuscript. L.O.L. supervised, reviewed, obtained funding, corrected the manuscript, and provided final approval of publication Funding: This study was partly supported by NIH grant numbers: DK120292, DK122734, and DK102325. for this manuscript. All authors have read and agreed to the published version of the manuscript. Conflicts of Interest: Dr. Lerman receives grant funding from Novo Nordisk and is an advisor to Weijian Funding: This study was partly supported by NIH grant numbers: DK120292, DK122734, and DK102325.
Publisher Copyright:
© 2020 by the authors.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Cell-derived extracellular vesicles (EVs) can be isolated from various body fluids, including urine. Urinary EVs have gained important recognition as potential diagnostic biomarkers in renal disease since their cargo includes nucleic acids, proteins, and other cellular components, which likely mirror the physiological and possibly pathophysiological state of cells along the nephron. Accumulating evidence highlights the feasibility of using EVs as biomarkers for diagnostic, prognostic, and therapeutic purposes in several forms of renal disease, such as acute kidney injury, glomerulonephritis, and renal transplantation. Additionally, exogenous delivery of EVs released in vitro by cells in culture may have salutary benefits for renal diseases. In this review, we introduce recent studies that attempt to identify urinary EVs as candidate biomarkers for human kidney diseases and consider their potential implication as a therapeutic option in key kidney diseases.
AB - Cell-derived extracellular vesicles (EVs) can be isolated from various body fluids, including urine. Urinary EVs have gained important recognition as potential diagnostic biomarkers in renal disease since their cargo includes nucleic acids, proteins, and other cellular components, which likely mirror the physiological and possibly pathophysiological state of cells along the nephron. Accumulating evidence highlights the feasibility of using EVs as biomarkers for diagnostic, prognostic, and therapeutic purposes in several forms of renal disease, such as acute kidney injury, glomerulonephritis, and renal transplantation. Additionally, exogenous delivery of EVs released in vitro by cells in culture may have salutary benefits for renal diseases. In this review, we introduce recent studies that attempt to identify urinary EVs as candidate biomarkers for human kidney diseases and consider their potential implication as a therapeutic option in key kidney diseases.
KW - Biomarkers
KW - Exosomes
KW - Kidney diseases
KW - Urine
UR - http://www.scopus.com/inward/record.url?scp=85084824234&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084824234&partnerID=8YFLogxK
U2 - 10.3390/diagnostics10050311
DO - 10.3390/diagnostics10050311
M3 - Review article
AN - SCOPUS:85084824234
SN - 2075-4418
VL - 10
JO - Diagnostics
JF - Diagnostics
IS - 5
M1 - diagnostics10050311
ER -